The role of dopamine and glutamate modulation in Huntington disease

Behavioural Neurology

Volumn 26, Issue 4, 2013, Pages 255-263

  Mittal, Sumeer K ^a   Eddy, Clare ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Anti dopaminergic; anti glutamatergic; dopamine; glutamate; Huntington's disease; pharmacotherapy; treatment

Indexed keywords

AMANTADINE; CLOZAPINE; PLACEBO; RILUZOLE; SULPIRIDE; TETRABENAZINE;

AGITATION; ANXIETY; ARTICLE; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FOLLOW UP; HUMAN; HUNTINGTON CHOREA; HYPERSALIVATION; INSOMNIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTLESSNESS; SIDE EFFECT; SUICIDAL IDEATION; SUICIDE; WALKING DIFFICULTY;

EID: 84876240346     PISSN: 09534180     EISSN: 18758584     Source Type: Journal    
DOI: 10.3233/BEN-2012-120268     Document Type: Article

References (25)

1. F.Walker, Huntington's Disease. Seminar, Lancet 369 (2007), 218-228.
2. C.A. Ross and S.J. Tabrizi, Huntington's disease: frommolecular pathogenesis to clinical treatment, Lancet 10 (2011), 83-98.
3. D. Craufurd, J.C. Thompson and J.S. Snowden, Behavioural changes in Huntington's disease, Neuropsychiatry Neuropsychol Behav Neurol 14 (2001), 219-226.
4. A. Montoya, B.H. Price, M. Menear and M. LePage, Brain imaging and cognitive dysfunctions in Huntington's disease, J Psychiatry Neurosci 31 (2006), 21-29.
5. A.M. Veronique, C. Cepeda and M.S. Levine, Dopamine and glutamate in Huntington's disease: A Balancing Act, CNS Neurosci Ther 16 (2010), 163-178.
6. D.Moher, A. Liberati, J. Tetzlaff and D.G. Altman, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement, PLoS Med 6 (2009), 1-6.
7. Huntington Study Group. Unified Huntington's disease rating scale: Reliabilty and consistency, Mov Disord 11 (1996), 136-142.
8. J. Jankovic, Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study, Ann Neurol 11 (1982), 41-47. (Pubitemid 12209517)
9. D. Paleacu, Tetrabenazine in the treatment of Huntington's disease, Neuropsychiatr Dis Treat 3 (2007), 545-551. (Pubitemid 350090285)
10. J.D. Erickson, M.K. Schafer, T.I. Bonner, L.E. Eiden and E. Weihe, Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter, Proc Natl Acad Sci USA 93 (1996), 5166-5171. (Pubitemid 26162890)
11. D.J. Pettibone, J.A. Totaro and A.B. Pflueger, Tetrabenazineinduced depletion of brain monoamines: characterization and interaction with selected anti-depressants, Eur J Pharmacol 102 (1984), 425-430. (Pubitemid 14064081)
12. A. Pletscher, A. Brossi and K.F. Grey, Benzoquinolizine derivatives: A new class of monoamine decreasing drugs with psychotropic action, Int Rev Neurobiol 4 (1962), 275-306.
13. O.R. Adam and J. Jankovic, Symptomatic treatment of Huntington Disease, Neurotherapeutics 5 (2008), 181-197. (Pubitemid 351446213)
14. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease. A randomised controlled trial, Neurology 66 (2006), 366-372.
15. S. Frank, W. Ondo, S. Fahn, C. Hunter, D. Oakes, S. Plumb, F. Marshall, I. Shoulson, S. Eberly, F. Walker, S. Factor, V. Hunt A. Shinaman and J. Jankovic, A study of chorea after tetrabenazine withdrawal in patients with huntington disease, Clin Neuropharmacol 31 (2008), 127-133. (Pubitemid 351787108)
16. N. Quinn and C.D. Marsden, A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia. Sulpiride trial in HD and Tardive dyskinesia patients, J Neurol Neurosurg Psychiatry 47 (1984), 844-847. (Pubitemid 14059377)
17. F. Girotti, F. Carella, G. Scigliano, M.P. Grassi, P. Soliveri, P. Giovannini, E. Parati and T. Carceni, Effect of neuroleptic treatment on involuntary movements and motor performances in Huntington's disease, J Neurol Neurosurg Psychiatry 47 (1984), 848-852. (Pubitemid 14059378)
18. J. Deroover, F. Baro, R.P. Bourguignon and P. Smets, Tiapride versus placebo: A double-blind comparative study in the management ofHuntington's chorea, Curr Med Res Opin 9 (1984), 329-338. (Pubitemid 15180157)
19. J.P.P. Van Vugt, S. Siesling, M. Vergeer, E.A. Van der Velde and R.A.C. Roos, Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study, J Neurol Neurosurg Psychiatry 63 (1997), 35-39. (Pubitemid 27317358)
20. E.D. Caine, R.J. Polinsky, R. Kartzinel and M.H. Ebert, The trial use of clozapine for abnormal involuntary movement disorders, Am J Psychiatry 324 (1979), 746-754.
21. C. Lucetti, P. Del Dotto, G. Gambaccini, G. Dell' Agnello, S. Bernardini, G. Rossi, L.Murri and U. Bonuccelli, IV amantadine improves chorea in Huntington's disease, Neurology 60 (2003), 1995-1997.
22. P. O'Suilleabhain and R.B. Dewey, A randomised trial of amantadine in huntington disease, Arch Neurol 60 (2003), 996-998. (Pubitemid 36858360)
23. Huntington Study Group. Dosage effects of riluzole in Huntington's disease. Amulticentre placebo-controlled study, Neurology 61 (2003), 1551-1556.
24. G.B. Landwehrmeyer, B. Dubois, J. Garcia de Yebenes, B. Kremer,W. Gaus, P.H. Kraus, H. Przuntek, M. Dib, A. Doble, W. Fischer and A.C. Ludolph, European Huntington's Disease Initiative Study Group. Riluzole in Huntington's Disease: A 3-year randomised controlled study, Ann Neurol 62 (2007), 262-272. (Pubitemid 47525402)
25. A.K. Ho, A.S. Gilbert, S.L. Mason, A.O. Goodman and R.A. Barker, Health-related quality of life in Huntington's disease: Which factors matter most? Mov Disord 24 (2009), 574-578.